The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related and demyelinating disorders such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.
August 15th 2025
A new study reveals rituximab outperforms cladribine in managing MRI disease activity in relapsing multiple sclerosis over 4.5 years.
Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD
August 29th 2022Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]
The Impact of Polypharmacy on Cognitive Health in MS
August 22nd 2022Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, discuss the impact of polypharmacy on cognitive health and share their thoughts on deciding when to cease treatments in patients with multiple sclerosis.
Germinal Center Activity Shows Potential As Target of Rituximab in NMOSD
August 17th 2022Data assessing samples of deep cervical lymph node aspirates and blood suggest that germinal center activity was associated with clinical relapses in individuals with neuromyelitis optica spectrum disorder.
Long-term Immunosuppression Treatment Is Suitable for Patients With NMOSD
August 16th 2022Data suggest that long-term treatment with immunosuppression therapies, such as rituximab, is generally appropriate for patients with neuromyelitis optica, though transverse myelitis might indicate a higher risk of relapse post discontinuation.
CNM-Au8 Displays Positive Topline Results in Multiple Sclerosis, Supportive of Phase 3 Trial
August 16th 2022Clene Nanomedicine’s gold nanocrystal suspension treatment showed significant improvements in Low Contrast Letter Acuity and Multiple Sclerosis Functional Composite scores among individuals with relapsing multiple sclerosis.